German Carmakers Funded Tests of Diesel Fumes on Monkeys and Humans

News reports reveal that Volkswagen, Daimler, and BMW funded the organization that conducted the studies.

Jan 29, 2018
Diana Kwon


Update (January 30): Following the reports of EUGT-funded fume tests, Volkswagen has suspended its head of external relations and sustainability, Thomas Steg, according to a statement released by the company today. “We are currently in the process of investigating the work of the EUGT, which was dissolved in 2017, and drawing all the necessary consequences,” Matthias Müller, Volkswagen’s CEO, says in the press release. “Mr. Steg has declared that he will assume full responsibility. I respect his decision.”

In 2014, scientists in a lab in Albuquerque, New Mexico, exposed 10 monkeys in airtight chambers to fumes from diesel-fueled cars while the animals watched cartoons, The New York Times reported last week (January 25). This experiment, which was part of an effort to prove that newer diesel vehicles were cleaner and less harmful than older ones, was sponsored by the European Research Group on Environment and Health in the Transport Sector (EUGT), an organization funded entirely by three German carmakers—Volkswagen, Daimler, and BMW.

Over the weekend, the German newspaper Stuttgarter Zeitung revealed a set of parallel experiments by the same organization examined the effects of nitrogen dioxide (NO2)—a pollutant found in diesel emissions—on 25 healthy human subjects that took place in Aachen, a city in Western Germany. “No reactions to inhaled NO2 could be detected,” according to results published by EUGT in 2016, Stuttgarter Zeitung reported (translated from German by Google Translate).

According to The New York Times, EUGT did not conduct any research itself, rather, it hired scientists to conduct investigations that would “defend the use of diesel,” using research that, among other things, challenged the World Health Organization’s classification of the fuel as a carcinogen.

Car industry-sponsored research “all has the same fundamental aim,” Joachim Heinrich, an environmental health expert at the University of Munich, tells The New York Times. “[N]amely to weaken or discredit regulation—to say ‘the evidence is not that clear,’ ‘we shouldn’t take it so seriously,’ ‘we need to think more about it.’”

The three car companies responded to the reports: BMW and Daimler distanced themselves from the experiments, while Volkswagen asked for forgiveness. “Animal testing contradicts our own ethical standards,” Volkswagen, a company already facing backlash for cheating on emission tests, tweeted on Saturday, before the reports of the human studies were published. “We know that the scientific methods used by EUGT were wrong and apologise sincerely for this.”

“We expressly distance ourselves from the studies and the EUGT. . . We are appalled by the extent of the studies and their implementation,” Daimler says in a statement. “All of the research work commissioned with the EUGT was accompanied and reviewed by a research advisory committee consisting of scientists from renowned universities and research institutes—from selection through to the presentation of results.”

“The BMW Group in no way influenced the design or methodology of studies carried out on behalf of the EUGT,” BMW says in a statement (via Deutsche Welle).

German government officials spoke out Monday, condemning the tests. “That a whole branch of industry has apparently tried to discard scientific facts with such brazen and dubious methods makes the entire thing even more horrific,” Barbara Hendricks, the German environment minister, tells The Guardian. She adds that she is “appalled” that scientists had “made themselves available as willing supporters of such despicable experiments.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.